Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 18, Issue SUPPL. 2, 2007, Pages

  Pestalozzi, B ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; LETROZOLE; METHOTREXATE; PACLITAXEL; PLACEBO; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VITAMIN D;

ARTICLE; BONE DISEASE; BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CARCINOMA IN SITU; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT PLANNING;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; NEOPLASM STAGING; RISK ASSESSMENT;

EID: 38549148559     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm015     Document Type: Article

References (13)

1. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
4. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
5. Jakesz R, Kaumann M, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and the ARNO 95 trial. Lancet 2005; 366: 455-462.
6. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092 [erratum, N Engl J Med 2004; 351: 2641].
7. Goss PE, Ingle JN, Margino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG Ma.17. J Natl Cancer Inst 2005; 97: 1262-1271.
8. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-629.
9. http://www.adjuvantonline.com/breast.jsp
10. NCCN Clinical Practice Guidelines in Oncology Breast Cancer. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf [last accessed 26 February 2007).
11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
12. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
13. Joenssu H, Kollokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.